microbiology-2016_posters-accepted-abstracts

3 / 42

Page 62
Notes:
conferenceseries.com
Volume 7, Issue 6 (Suppl) J Bacteriol Parasito
ISSN: 2155-9597 JBP, an open access journal Microbiology 2016
November 28-29, 2016
November 28-29, 2016 Valencia, Spain
7th World Congress on
Microbiology
Yong Bong Kim et al., J Bacteriol Parasitol 2016, 7:6 (Suppl)
Comparative analysis of Middle East respiratory syndrome coronavirus subunit vaccine candidates in
mice
Yong Bong Kim, Sehyun Kim, Yeondong Cho, Hee-Jung Lee, Ki Hoon Park and Hanul Choi
Konkuk University, South Korea
Since Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012, MERS-CoV has spread from Middle East to
Europe, America and Asia. South Korea also affected by MERS-CoV and it has been a serious threat to public health. Until today
there is no available vaccine for MERS-CoV. Therefore, it is required to develop a vaccine against the MERS-CoV. It is well known
that MERS-CoV spike protein (S protein) has an important role in the host cell entrance and that makes many researchers working
on the subunit vaccine development using S protein. Especially receptor-binding domain (RBD) at the S protein is usually considered
for making recombinant antigen proteins. Jiang et al. reported that RBD is a critical neutralizing domain and the recombinant RBD
protein induced strong immune responses and neutralizing antibodies in mouse models. However, other region of MERS-CoV
S protein has not been studied well relatively. Here, our group selected several parts of MERS-CoV S protein according to some
properties, such as antigenicity and hydrophilicity and then we studied to compare an immunodominance of them. Six partial regions
from MERS-CoV S gene were cloned into pASK-IBA7 plus vector. Then they were transformed into E. coli Rosetta strain and each
clone was produced to soluble recombinant proteins and purified by strep-tag affinity chromatography. Each purified recombinant
protein was confirmed by Western blot assay using sera from MERS patient. Immunogenicity of these proteins was characterized
through animal experiment.
Biography
Young Bong Kim has completed his PhD from Sogang University in Korea and Postdoctoral studies from NIAID, NIH, USA. He is the Director of Institute of Global
Infectious Disease Control at Konkuk University. He has published more than 60 papers in reputed journals.